Exclusive Summary

• - Patent barriers are cleared; originator Metaglip launched in 2002 and is long off-patent, enabling immediate filing/distribution in most countries.
• - >530 million people live with diabetes and 81% are in LMICs, sustaining strong demand for low-cost oral dual therapy.
• - Guidelines endorse metformin first-line with sulfonylureas as a cost-effective add-on; the 250/2.5 mg low dose supports initiation/titration and mitigates hypoglycemia risk.
• - Competition is intense in the US (≥10 ANDAs) but lighter in many emerging markets, where the low-dose strength offers differentiation.
• - APIs comply with JP/BP/USP/EP/KP and TT is available, easing multi-region registration and localization (note: no China-agency engagement for Vietnam).